Acumen Pharmaceuticals, Inc. (ABOS): Form 8-K filed 2026-11-05

Items reported

Item 1.02: Termination of a Material Definitive Agreement
A material agreement was terminated other than by expiring on its stated date. The company describes the agreement, the circumstances of the termination and any material early-termination penalties.
Item 2.05: Cost Associated with Exit or Disposal Activities
The company committed to an exit or disposal plan, such as a restructuring, facility closure or workforce reduction, under which it expects to incur material charges.
Item 9.01: Financial Statements and Exhibits
Lists the financial statements, pro forma information and exhibits filed with the report. It almost always accompanies another Item and is rarely news on its own.

Type	Description	Document
8-K	8-K	abos-20261101.htm

This page lists what the filing reports; it does not summarize or interpret it. Read the original documents on SEC EDGAR. How to read an 8-K.